Suppr超能文献

患者血清中无基因组乙肝病毒颗粒水平作为监测抗病毒治疗反应的潜在标志物。

Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy.

作者信息

Luckenbaugh L, Kitrinos K M, Delaney W E, Hu J

机构信息

Department of Microbiology and Immunology, Penn State University College of Medicine, Hershey, PA, USA.

出版信息

J Viral Hepat. 2015 Jun;22(6):561-70. doi: 10.1111/jvh.12361. Epub 2014 Nov 14.

Abstract

Complete virions of hepatitis B virus (HBV) contain a DNA genome that is enclosed in a capsid composed of the HBV core antigen (HBcAg), which is in turn surrounded by a lipid envelope studded with viral surface antigens (HBsAg). In addition, HBV-infected cells release subviral particles composed of HBsAg only (HBsAg 'spheres' and 'filaments') or HBsAg enveloping HBcAg but devoid of viral DNA ('empty virions'). The hepatitis B e antigen (HBeAg), a soluble antigen related to HBcAg, is also secreted in some HBV-infected patients. The goals of this study were to explore the levels of empty virions in HBV-infected patients before and during therapy with the nucleotide analog tenofovir disoproxil fumarate (TDF) that inhibits HBV DNA synthesis and the relationships of empty virions to complete virions, HBsAg and HBeAg. HBV DNA, HBcAg and HBsAg levels were determined in serum samples from 21 patients chronically infected with HBV and enrolled in clinical TDF studies. Serum levels of empty virions were found to exceed levels of DNA-containing virions, often by ≥ 100-fold. Levels of both empty and complete virions varied and were related to the HBeAg status. When HBV DNA replication was suppressed by TDF, empty virion levels remained unchanged in most but were decreased (to the limit of detection) in some patients who also experienced significant decrease or loss of serum HBsAg. In conclusion, empty virions are present in the serum of chronic hepatitis B patients at high levels and may be useful in monitoring response to antiviral therapy.

摘要

乙型肝炎病毒(HBV)的完整病毒粒子含有一个DNA基因组,该基因组被包裹在由乙肝核心抗原(HBcAg)组成的衣壳中,而衣壳又被镶嵌有病毒表面抗原(HBsAg)的脂质包膜所包围。此外,受HBV感染的细胞会释放仅由HBsAg组成的亚病毒颗粒(HBsAg“小球”和“细丝”)或包裹着HBcAg但不含病毒DNA的HBsAg(“空病毒粒子”)。乙肝e抗原(HBeAg)是一种与HBcAg相关的可溶性抗原,在一些HBV感染患者中也会分泌。本研究的目的是探讨在接受抑制HBV DNA合成的核苷酸类似物替诺福韦酯(TDF)治疗之前和治疗期间,HBV感染患者体内空病毒粒子的水平,以及空病毒粒子与完整病毒粒子、HBsAg和HBeAg之间的关系。对21名慢性感染HBV并参与TDF临床研究的患者的血清样本进行了HBV DNA、HBcAg和HBsAg水平的测定。结果发现,血清中空病毒粒子的水平超过含DNA病毒粒子的水平,通常高出≥100倍。空病毒粒子和完整病毒粒子的水平均有所变化,且与HBeAg状态有关。当TDF抑制HBV DNA复制时,大多数患者的空病毒粒子水平保持不变,但在一些血清HBsAg也显著下降或消失的患者中,空病毒粒子水平降低(至检测限)。总之,空病毒粒子在慢性乙型肝炎患者血清中高水平存在,可能有助于监测抗病毒治疗的反应。

相似文献

1
Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy.
J Viral Hepat. 2015 Jun;22(6):561-70. doi: 10.1111/jvh.12361. Epub 2014 Nov 14.
5
Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
J Hepatol. 2011 Jul;55(1):61-8. doi: 10.1016/j.jhep.2010.10.027. Epub 2010 Dec 5.
9
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
J Hepatol. 2017 Nov;67(5):918-924. doi: 10.1016/j.jhep.2017.07.012. Epub 2017 Jul 21.

引用本文的文献

1
Hepatitis B Virus Nucleocapsid Assembly.
J Mol Biol. 2025 Apr 30:169182. doi: 10.1016/j.jmb.2025.169182.
2
Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors.
PLoS Pathog. 2025 Feb 10;21(2):e1012920. doi: 10.1371/journal.ppat.1012920. eCollection 2025 Feb.
3
From the Cytoplasm into the Nucleus-Hepatitis B Virus Travel and Genome Repair.
Microorganisms. 2025 Jan 14;13(1):157. doi: 10.3390/microorganisms13010157.
4
Paired Capture and FISH Detection of Individual Virions Enable Cell-Free Determination of Infectious Titers.
ACS Sens. 2023 Jul 28;8(7):2563-2571. doi: 10.1021/acssensors.3c00239. Epub 2023 Jun 27.
5
Live Cell Imaging Reveals HBV Capsid Translocation from the Nucleus To the Cytoplasm Enabled by Cell Division.
mBio. 2023 Apr 25;14(2):e0330322. doi: 10.1128/mbio.03303-22. Epub 2023 Feb 21.
8
Insights into Hepatitis B Virus DNA Integration-55 Years after Virus Discovery.
Innovation (Camb). 2020 Aug 5;1(2):100034. doi: 10.1016/j.xinn.2020.100034. eCollection 2020 Aug 28.
9
Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma.
Microorganisms. 2021 Aug 23;9(8):1787. doi: 10.3390/microorganisms9081787.

本文引用的文献

1
Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings.
PLoS One. 2014 Mar 4;9(3):e89789. doi: 10.1371/journal.pone.0089789. eCollection 2014.
4
Antigenic switching of hepatitis B virus by alternative dimerization of the capsid protein.
Structure. 2013 Jan 8;21(1):133-142. doi: 10.1016/j.str.2012.10.017. Epub 2012 Dec 6.
7
Effectiveness of hepatitis B treatment in clinical practice.
Gastroenterology. 2012 May;142(6):1360-1368.e1. doi: 10.1053/j.gastro.2012.01.044.
8
Secretion of genome-free hepatitis B virus--single strand blocking model for virion morphogenesis of para-retrovirus.
PLoS Pathog. 2011 Sep;7(9):e1002255. doi: 10.1371/journal.ppat.1002255. Epub 2011 Sep 22.
9
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.
Hepatol Int. 2013 Jun;7(2):327-34. doi: 10.1007/s12072-011-9282-y. Epub 2011 Jun 19.
10
Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Gastroenterology. 2010 Oct;139(4):1207-17. doi: 10.1053/j.gastro.2010.06.053. Epub 2010 Jun 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验